The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1145
December 9, 2002
View Complete Issue         Table of Contents 2019 
Adefovir (Hepsera) for Chronic Hepatitis B Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Adefovir (Hepsera) for Chronic Hepatitis B Infection
December 9, 2002 (Issue: 1145)
Adefovir dipivoxil (Hepsera - Gilead), a nucleotide analog, has been approved by the FDA for oral treatment of chronic active infection with hepatitis B virus (HBV). In 1999, because of concerns about renal toxicity, the FDA rejected a higher-dosage...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Adefovir (Hepsera) for Chronic Hepatitis B Infection
Article code: 1145b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.